Beyfortus and Abrysvo together: what to know
Two different tools now exist to protect newborns from RSV: the maternal RSV vaccine (Abrysvo), given during pregnancy, and Beyfortus (nirsevimab), a monoclonal antibody given to infants after birth. Many expectant parents who received Abrysvo during pregnancy wonder: does my baby still need Beyfortus? Can they get both safely? The answer depends on your timing and your baby's situation.
What each one does
Abrysvo (maternal RSV vaccine) is given to you during pregnancy at 32–36 weeks gestation. Your body produces RSV antibodies, which cross the placenta and enter your baby's bloodstream before birth. Your baby is born with passive immunity that lasts through the first several months of life — ideally covering the most vulnerable newborn window.
Beyfortus (nirsevimab) is a pre-formed monoclonal antibody given by injection directly to your baby, typically at birth or at the first well-child visit during RSV season. It provides the same type of passive antibody protection as the maternal vaccine but delivered after birth, with no dependency on the placenta transfer.
The current guidance: generally one or the other
The CDC's current recommendation is that infants should receive either maternal Abrysvo during pregnancy or Beyfortus after birth — not routinely both. The reasoning: if the maternal vaccine was given at the right time and the baby was born at term, the transferred antibodies are expected to provide adequate protection through the first RSV season without an additional dose of Beyfortus.
Why not both routinely? High levels of maternal antibodies can actually interfere with the effectiveness of some infant vaccines by neutralizing them before the baby's immune system can respond. While Beyfortus itself isn't a traditional vaccine (it's a passive antibody, not a live or inactivated pathogen), the concern about redundant protection and resource allocation — Beyfortus has faced supply constraints — led to the "one or the other" guidance for healthy term infants.
When Beyfortus may still be recommended after Abrysvo
The guidance is not absolute. There are situations where your baby's doctor may recommend Beyfortus even if you received Abrysvo:
- Your baby was born prematurely — especially before 32 weeks, before significant placental antibody transfer could occur. A premature baby may have received minimal protection from the maternal vaccine and benefits from the direct protection of Beyfortus.
- Your baby has a chronic heart or lung condition — these infants are at higher risk for severe RSV and may benefit from maximum available protection.
- You received Abrysvo very close to 32 weeks — earlier in the eligible window, before your body had time to build and transfer robust antibody levels.
- Your baby is entering a second RSV season — Abrysvo protection is intended to cover the first RSV season only; second-season protection for high-risk infants may involve Beyfortus.
Your pediatrician will weigh your baby's specific gestational age, birth timing relative to RSV season, and any underlying conditions when making this call.
If you didn't receive Abrysvo during pregnancy
If you didn't receive the maternal RSV vaccine — whether because it wasn't offered, you declined, or your pregnancy didn't land in the eligible window — your baby enters the world without RSV antibody protection from that source. Beyfortus is then the primary protection option for your newborn through their first RSV season, and your pediatrician should offer it at the appropriate time.
Timing: when is Beyfortus given?
For babies born during RSV season (roughly October–March): Beyfortus is typically given at birth or before hospital discharge. For babies born outside RSV season: it's given at the first well-child visit that falls within RSV season — usually the 2-month or 4-month visit in fall.
If your baby turns 8 months before their first RSV season peaks, they may no longer be eligible for the standard dose (though high-risk infants can receive a second-season dose up to 24 months). Ask your pediatrician at your baby's 2-month visit about timing.
Is it safe to receive both?
There is no safety concern with an infant having both maternal-transferred Abrysvo antibodies and a Beyfortus injection. Both provide RSV-specific antibodies and the combination has been studied. The guidance against routine dual use is about necessity and resource allocation, not safety. If your doctor recommends Beyfortus despite you having received Abrysvo, it's safe to proceed.
Not medical advice. CDC recommendations for RSV protection evolve as new data emerges. Always confirm current guidance with your OB and pediatrician. In an emergency, call 911.